Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
New MGA Analysis of the Adalimumab Biosimilars Market in the United States

New MGA Analysis of the Adalimumab Biosimilars Market in the United States

Feb 21, 2023 | Analysis, Press Releases

New MGA Analysis of the Adalimumab Biosimilars Market in the United States Below is the press release from Biosimilars Council regarding the new report from MGA examining biosimilar competition for Humira (adalimumab) in the US market. Washington, D.C. (February 21,...
Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Jan 31, 2023 | Interviews

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug Celine Castronuovo | Bloomberg Law News “More than 1.4 million patients have used Humira globally, according to AbbVie. The drug takes up a huge chunk of Medicare spending in the US, with an HHS...
New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

Dec 8, 2022 | Analysis

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit. While patients and physicians play a role...
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Jul 14, 2022 | Analysis

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”  Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for...
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

May 26, 2022 | Analysis

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology...
Page 1 of 41234»
  • Analysis (38)
  • Books (3)
  • Events (15)
  • Interviews (48)
  • News (51)
  • Op-Eds (80)
  • Press Releases (4)
  • Testimony (20)
  • Health Care Workforce Shortages
    Health Care Workforce Shortages: An Updated LookFebruary 21, 2023
  • New MGA Analysis of the Adalimumab Biosimilars Market in the United StatesFebruary 21, 2023
  • Squawk Box tax policy
    MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy ProposalFebruary 13, 2023
  • Curb Drug Patent Abuse
    Bipartisan Senate Bill Aims to Curb Drug Patent AbuseFebruary 1, 2023
  • Humira rivals drive down cost
    Humira Rivals Set to Try to Drive Down Cost of Blockbuster DrugJanuary 31, 2023
  • patent thickets lost drug savings
    New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent ThicketsJanuary 26, 2023
  • Biosimilar Coverage in Commercial
    New MGA Analysis of Biosimilar Coverage in Commercial Medical BenefitDecember 8, 2022
  • Narrow House GOP Victory
    Narrow House GOP Victory Should Point Toward Policy Development AgendaDecember 6, 2022
  • Health Care Workforce Shortages
    Don’t Let Pandemic Fatigue Inhibit Pandemic PreparednessNovember 15, 2022
  • Pro-Growth Tax System.
    American Renewal: A Simpler, More Responsible, and Pro-Growth Tax SystemNovember 15, 2022
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact